ACADIA Pharmaceuticals, Inc.
3911 Sorrento Valley Boulevard
San Diego,
CA 92121
United States - Map
Phone: 858-558-2871
Fax: 858-558-2872
Web Site: http://www.acadia-pharm.com
| ACADIA Pharmaceuticals, Inc., a biopharmaceutical company, focuses on drug discovery and clinical development of novel treatments for central nervous system disorders. The company is developing a portfolio of four product candidates, including pimavanserin, which is being developed for three separate neurological and psychiatric indications in collaboration with Biovail. These indications include Parkinsons disease psychosis that is in Phase III development; adjunctive therapy for schizophrenia, which is in Phase III planning; and Alzheimers disease psychosis, for which ACADIA is planning to initiate a Phase II feasibility study. The company also has other products under development, including a product candidate in Phase II development for chronic pain; and a product candidate in Phase I development for glaucoma, both in collaboration with Allergan, as well as a program in IND-track development in collaboration with Meiji Seika Kaisha. The products in ACADIAs pipeline emanate from discoveries made using its proprietary drug discovery platform. The company, formerly known as Receptor Technologies, Inc., was founded in 1993 and is headquartered in San Diego, California. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Uli Hacksell Ph.D., 60
Chief Exec. Officer |
$
463.00K |
$
13.00K | Mr. Thomas H. Aasen C.P.A., 49
Chief Financial Officer, Principal Accounting Officer, VP, Sec. and Treasurer |
$
302.00K |
$
125.00K | Dr. Roger G. Mills M.D., 52
Exec. VP of Devel. |
$
361.00K |
$
0 |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.16% Nasdaq 0.00%
Profile
